<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palumbo, A.</style></author><author><style face="normal" font="default" size="100%">Hajek, R.</style></author><author><style face="normal" font="default" size="100%">Delforge, M.</style></author><author><style face="normal" font="default" size="100%">Kropff, M.</style></author><author><style face="normal" font="default" size="100%">Petrucci, M.T.</style></author><author><style face="normal" font="default" size="100%">Catalano, J.</style></author><author><style face="normal" font="default" size="100%">Gisslinger, H.</style></author><author><style face="normal" font="default" size="100%">Wiktor-Jȩdrzejczak, W.</style></author><author><style face="normal" font="default" size="100%">Zodelava, M.</style></author><author><style face="normal" font="default" size="100%">Weisel, K.</style></author><author><style face="normal" font="default" size="100%">Cascavilla, N.</style></author><author><style face="normal" font="default" size="100%">Iosava, G.</style></author><author><style face="normal" font="default" size="100%">Cavo, M.</style></author><author><style face="normal" font="default" size="100%">Kloczko, J.</style></author><author><style face="normal" font="default" size="100%">Bladé, J.</style></author><author><style face="normal" font="default" size="100%">Beksac, M.</style></author><author><style face="normal" font="default" size="100%">Spicka, I.</style></author><author><style face="normal" font="default" size="100%">Plesner, T.</style></author><author><style face="normal" font="default" size="100%">Radke, J.</style></author><author><style face="normal" font="default" size="100%">Langer, C.</style></author><author><style face="normal" font="default" size="100%">Yehuda, D.B.</style></author><author><style face="normal" font="default" size="100%">Corso, A.</style></author><author><style face="normal" font="default" size="100%">Herbein, L.</style></author><author><style face="normal" font="default" size="100%">Yu, Z.</style></author><author><style face="normal" font="default" size="100%">Mei, J.</style></author><author><style face="normal" font="default" size="100%">Jacques, C.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Continuous lenalidomide treatment for newly diagnosed multiple myeloma</style></title><secondary-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84860744403&amp;doi=10.1056%2fNEJMoa1112704&amp;partnerID=40&amp;md5=92a72feb0b7f2e00b2754367622f0d69</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">366</style></volume><pages><style face="normal" font="default" size="100%">1759 - 1769</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone- lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma. METHODS: We randomly assigned patients who were ineligible for transplantation to receive MPR-R (nine 4-week cycles of MPR followed by lenalidomide maintenance therapy until a relapse or disease progression occurred [152 patients]) or to receive MPR (153 patients) or MP (154 patients) without maintenance therapy. The primary end point was progression-free survival. RESULTS: The median follow-up period was 30 months. The median progression-free survival was significantly longer with MPR-R (31 months) than with MPR (14 months; hazard ratio, 0.49; P&lt;0.001) or MP (13 months; hazard ratio, 0.40; P&lt;0.001). Response rates were superior with MPR-R and MPR (77% and 68%, respectively, vs. 50% with MP; P&lt;0.001 and P = 0.002, respectively, for the comparison with MP). The progression-free survival benefit associated with MPR-R was noted in patients 65 to 75 years of age but not in those older than 75 years of age (P = 0.001 for treatment-by-age interaction). After induction therapy, a landmark analysis showed a 66% reduction in the rate of progression with MPR-R (hazard ratio for the comparison with MPR, 0.34; P&lt;0.001) that was age-independent. During induction therapy, the most frequent adverse events were hematologic; grade 4 neutropenia was reported in 35%, 32%, and 8% of the patients in the MPR-R, MPR, and MP groups, respectively. The 3-year rate of second primary tumors was 7% with MPR-R, 7% with MPR, and 3% with MP. CONCLUSIONS: MPR-R significantly prolonged progression-free survival in patients with newly diagnosed multiple myeloma who were ineligible for transplantation, with the greatest benefit observed in patients 65 to 75 years of age. (Funded by Celgene; MM-015 ClinicalTrials.gov number, NCT00405756.) Copyright © 2012 Massachusetts Medical Society.</style></abstract><issue><style face="normal" font="default" size="100%">19</style></issue><notes><style face="normal" font="default" size="100%">Cited By :362Export Date: 21 February 2017</style></notes></record></records></xml>